Maze Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, could address the majority of the over 1M APOL1 kidney disease patients and is 100-times more potent than Vertex’s inaxaplin, the analyst tells investors in a research note. In addition, the firm says MZE782, a novel oral SLC6A19 inhibitor, is a potential first-in-class treatment for chronic kidney disease with a “de-risked” developmental path in phenylketonuria. Both assets have blockbuster potential and a higher than average probability of technical success, contends TD.